香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Xuanzhu Biopharmaceutical Co., Ltd. 軒竹生物科技股份有限公司 （一家於中華人民共和國註冊成立的股份有限公司） （股份代號：2575） 執行董事兼總經理辭任 董 事 會 謹 此 向 李 博 士 為 本 公 司 作 出 之 寶 貴 貢 獻 致 以 衷 心 感 謝。 承董事會命 軒 竹 生 物 科 技 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈 李 嘉 逵 博 士（「李博士」）辭 任 本 公 司 執 行 董 事 及 總 經 理，以 投 放 更 多 時 間 於 其 他 業 務 承 擔（「辭 任」）。 李博士確認(i)彼 與 董 事 會 並 無 任 何 意 見 分 歧；及(ii)並無有關辭任之其他事宜 須 提 請 聯 交 所 及 本 ...

Core Viewpoint - The "Technology Empowerment · Capital Breakthrough" sharing conference revealed the list of outstanding companies, highlighting the recognition of exceptional performance in the IPO sector [1] Group 1: Company Recognition - XuanZhu Biotechnology - B (2575.HK) won the "Annual Outstanding Investment Value IPO" award at the "Golden Grid Award" annual selection, acknowledging its strong performance in core business and significant growth potential in its industry [1]

Core Viewpoint - The "Annual Outstanding Investment Value IPO" awards recognize new listed companies that excel in core business, performance growth, and shareholder value creation, highlighting their significant growth potential and competitive advantages in their respective industries [4]. Group 1: Award Recipients - Eight companies received the "Annual Outstanding Investment Value IPO" award, including Different Group (06090.HK), Cao Cao Travel (02643.HK), Dipo Technology (01384.HK), Geek+ (02590.HK), Leshu (02698.HK), Tudatong (02665.HK), Xuan Bamboo Biotechnology-B (02575.HK), and Yingshi Innovation (688775.SH) [1]. - The ranking of the award recipients is not in any particular order and is based on the first letter of the company names [1]. Group 2: Evaluation Criteria - The evaluation for the awards was conducted through quantitative data analysis and an expert review panel [4]. - The awards aim to create a reference value for listed companies and unicorn companies within the investment community, emphasizing a global perspective with a focus on China [4]. Group 3: Coverage of the Awards - The "Golden Award" listing company evaluation covers all listed companies and unicorns on the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, American Stock Exchange, and NASDAQ [4].

Core Viewpoint - XuanZhu Biotech's stock price has surged significantly, reflecting strong investor confidence in its innovative capabilities, with a cumulative increase of 700% since its IPO as of December 11 [1] Group 1: Company Performance - XuanZhu Biotech has launched three innovative drugs in three years, demonstrating its efficient R&D conversion system [5] - The company has successfully commercialized three innovative drugs in the "digestion + oncology" fields within a short span, showcasing its ability to address clinical pain points [5][6] - The stock price increase is attributed to the clinical value realization of its core products and the company's effective R&D strategy [5][7] Group 2: Product Details - Annelazole Sodium addresses two major clinical pain points in the PPI market: genetic adaptability and renal safety, achieving a significant reduction in efficacy differences among patients with different genetic types [6] - The drug has been included in the national medical insurance directory in its first year, filling a clinical demand gap [6] - The two oncology drugs, Pyrocil and Diroac, target unmet needs in HR+/HER2- breast cancer and ALK-positive NSCLC, respectively, enhancing the company's oncology pipeline [7][12] Group 3: Market Potential - The market for CDK4/6 inhibitors for breast cancer is projected to reach 9.8 billion yuan by 2030, with Pyrocil expected to penetrate the market rapidly due to its competitive clinical data [11] - The potential market for ALK inhibitors in NSCLC is estimated to reach 7.8 billion yuan by 2030, indicating a significant growth opportunity for Diroac [13] - The innovative drugs' clinical data support a shift in the industry valuation focus from pipeline thickness to individual product value density, positioning XuanZhu Biotech as a potential leader in niche markets [15]

Group 1: 52-Week Highs - A total of 44 stocks reached their 52-week highs as of December 12, with notable performers including Yuanmei Optoelectronics (08311) at 105.56%, Jinglian Group (01751) at 25.54%, and Xuan Bamboo Biotechnology - B (02575) at 23.60% [1] - The closing prices and peak prices for the top three stocks are as follows: Yuanmei Optoelectronics closed at 0.154 with a peak of 0.185, Jinglian Group closed at 1.850 with a peak of 2.310, and Xuan Bamboo Biotechnology - B closed at 82.950 with a peak of 96.900 [1] Group 2: 52-Week Lows - The report also highlighted stocks that reached their 52-week lows, with notable declines including Times China Holdings (01233) at -13.79%, Cornerstone Holdings (01592) at -11.36%, and HMVOD Video (08103) at -9.09% [2] - The closing prices and lowest prices for the top three declining stocks are as follows: Times China Holdings closed at 0.106 with a low of 0.100, Cornerstone Holdings closed at 0.198 with a low of 0.195, and HMVOD Video closed at 0.129 with a low of 0.120 [2]

Core Viewpoint - XuanZhu Bio-B (02575) shares surged over 20%, reaching a new high of 93.05 HKD, driven by the inclusion of its innovative drug XuanYueNing in the national basic medical insurance drug list, enhancing affordability and accessibility for patients [1] Group 1: Company Developments - XuanZhu Bio-B's stock price increased by 19.51%, trading at 92.5 HKD with a transaction volume of 18.7759 million HKD at the time of reporting [1] - The recent announcement regarding XuanYueNing's inclusion in the national insurance list is expected to positively impact the drug's market promotion and sales scale, contributing to the company's long-term operational development [1] Group 2: Industry Insights - The pharmaceutical industry is witnessing a return to product strength, with XuanZhu Bio-B set to receive approvals for two new oncology drugs by 2025, marking a significant realization of its innovative value [1] - The drug Pirlosilib is strategically positioned in the breast cancer market with differentiated indications, while Dirocetam offers high intracranial penetration and over 91% IC-ORR, addressing unmet needs in brain metastasis treatment [1] - Together with Annelaz Sodium, these products form a "three-horse" commercial framework that lays a solid foundation for the company's long-term growth [1]

Group 1 - The stock of Xuan Bamboo Bio-B (02575.HK) surged over 20%, reaching a new high of 93.05 HKD [1] - As of the latest update, the stock increased by 19.51%, trading at 92.5 HKD with a transaction volume of 18.7759 million HKD [1]

Core Viewpoint - XuanZhu Bio-B (02575) shares surged over 20%, reaching a new high of HKD 93.05, driven by the inclusion of its innovative drug XuanYueNing in the national basic medical insurance drug list, enhancing affordability and accessibility for patients [1] Group 1: Company Developments - The recent announcement regarding XuanYueNing's inclusion in the national basic medical insurance drug list is expected to positively impact the company's long-term operational development by promoting market penetration and increasing sales scale [1] - The company is set to achieve significant milestones with two new oncology drugs expected to be approved by 2025, which will solidify its innovative value in the pharmaceutical industry [1] Group 2: Product Insights - The oncology drug Piroxil is strategically positioned in the breast cancer market with a differentiated indication, while Dirocizumab offers high intracranial penetration and over 91% IC-ORR, addressing a gap in brain metastasis treatment [1] - Together with Anailaz Sodium, these products form a "three-horsepower" commercial framework that lays a solid foundation for the company's long-term growth [1]

Core Viewpoint - Xuan Bamboo Biotech-B (02575) saw its stock price increase by over 20%, reaching a new high of 93.05 HKD, driven by the inclusion of its innovative drug Xuan Yuen Ning in the national basic medical insurance drug list, enhancing affordability and accessibility for patients [1][1]. Company Developments - The recent announcement regarding Xuan Yuen Ning's inclusion in the national basic medical insurance drug list is expected to positively impact the company's long-term operational development by promoting market penetration and increasing sales scale [1][1]. - The company is positioned to benefit from the approval of two new oncology drugs by 2025, which are critical for realizing its innovative value [1][1]. Product Insights - The oncology drug pipeline includes Pirlosil with a differentiated indication targeting breast cancer, and Diroak, which offers high intracranial penetration and over 91% IC-ORR, addressing a gap in brain metastasis treatment [1][1]. - These products, along with Annelazole Sodium, form a "three-horse" commercial framework that lays a solid foundation for the company's long-term growth [1][1].

Core Insights - The global biotechnology sector is evolving with a shift from "storytelling" to "product validation," reflecting a fundamental change in competitive logic within the Chinese pharmaceutical industry [1] - XuanZhu Biotech (02575) is set to realize its tumor pipeline in 2025, with the approval of its CDK4/6 inhibitor, Palbociclib, and ALK inhibitor, Lorlatinib, alongside its previously launched product, Anailaz Sodium, forming a "three-horse carriage" for commercialization [1] Product Performance - Palbociclib has shown significant clinical potential in HR+/HER2- advanced breast cancer treatment, with a median progression-free survival (mPFS) not yet reached, outperforming control groups with mPFS of 18.43 months and 19.55 months [2] - The objective response rate (ORR) for Palbociclib reached 63.5%, a 21 percentage point increase over the control group, and the risk of disease progression or death was reduced by 47%, with a 64% reduction in liver metastasis patients [2] - The safety profile of Palbociclib is manageable, with common adverse events being grade 1-2, which can be effectively managed through supportive care or dose adjustments [2] Market Strategy - The approval of Palbociclib for first-line treatment marks a comprehensive coverage from salvage therapy to first-line initial treatment, enhancing its market penetration potential [3] - The dual-mode strategy of "single-agent + combination" aligns well with clinical needs, expanding the patient base significantly for future market penetration [3] Competitive Edge of Lorlatinib - Lorlatinib targets ALK-positive NSCLC brain metastases, achieving an intracranial objective response rate (IC-ORR) exceeding 91%, addressing a critical unmet clinical need [4] - The drug's design allows for effective penetration of the blood-brain barrier, providing a significant advantage over traditional ALK inhibitors [5] - Clinical data shows Lorlatinib's ORR at 88.5% and mPFS of 31.3 months, doubling the duration compared to Crizotinib, with a notable IC-ORR of 91.7% in brain metastasis patients [5] Conclusion - XuanZhu Biotech's two new tumor drugs are set to be approved in 2025, with Palbociclib and Lorlatinib addressing specific market needs and forming a solid foundation for the company's long-term growth alongside Anailaz Sodium [6]